Comorbidity

THE DERMATOLOGY FOUNDATION AND SKIN OF COLOR SOCIETY BESTOW THE FIRST-EVER SANOFI AND REGENERON DIVERSITY, EQUITY, AND INCLUSION MID-CAREER AWARD ON DONALD A. GLASS II, MD, PhD, FAAD

Retrieved on: 
Tuesday, March 19, 2024
SOCS, Autoimmunity, University, Glass, Regeneron Pharmaceuticals, Associate, Health equity, Genetics, Patient, DF, Research, Diversity, American Academy, Doctor of Philosophy, MBA, Skin, University of Massachusetts, MPH, Comorbidity, FAAD, Bangladesh Technical Education Board, DEI, Vitiligo, Medicine, Pharmaceutical industry

CHICAGO, March 19, 2024 /PRNewswire/ -- The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Donald A. Glass II, MD, PhD, FAAD, is the 2024 recipient of the first-ever Sanofi and Regeneron Diversity, Equity, and Inclusion (DEI) Mid-Career Award, given to support his research into "Genetics, Comorbidities and their Association with Keloids."

Key Points: 
  • A nationally recognized keloids expert, Dr. Glass is an Associate Professor at the University of Texas Southwestern Medical Center in Dallas, Texas.
  • He served as 2021-2022 President of the Skin of Color Society.
  • The Sanofi and Regeneron DEI Mid-Career Award was developed especially for the exceptional mid-career investigator with an established trajectory of excellence in basic, clinical or translational science.
  • Our sincere congratulations to Dr. Glass, the outstanding first award recipient for this highly competitive award—and our sincere gratitude to Sanofi and Regeneron for making the award possible."

WebMD Health Services Announces Strategic Partnership with Verily's Onduo to Enhance Employee Health and Well-Being

Retrieved on: 
Thursday, March 14, 2024
Health care, Health, Learning, Partnership, Physician, Diabetes, Risk, Patient, Biomarker, Pharmacist, Telehealth, WebMD, Quality of life, Health equity, CDC, Comorbidity, Prediabetes, Hypertension

PORTLAND, Ore., March 14, 2024 /PRNewswire/ -- WebMD Health Services today announced a new partnership with Onduo, a virtual care management solution from Verily, an Alphabet precision health technology company.

Key Points: 
  • PORTLAND, Ore., March 14, 2024 /PRNewswire/ -- WebMD Health Services today announced a new partnership with Onduo, a virtual care management solution from Verily, an Alphabet precision health technology company.
  • This partnership addresses members' needs by combining cutting-edge technology with comprehensive health and well-being solutions.
  • WebMD Health Services will integrate Onduo's virtual care solution into WebMD ONE, a comprehensive health and well-being platform, providing a seamless experience for users.
  • Through this partnership with Onduo, WebMD is expanding how we support members with complex care needs beyond condition management, health coaching and digital programs to include access to devices and telemedicine.

Best Life Insurance Plans for Multiple Sclerosis (MS) Patients - Our Top Picks for 2024

Retrieved on: 
Tuesday, March 12, 2024
Survival, ICC, Patient, History, SBLI, Legal & General, Research, Risk, Policy, Lincoln National Corporation, AEGON, Privacy, Hypertension, Disability, Database, Frontiers Media, Journal, Prescription, Neurosurgery, Roger Hawkins (drummer), MD, Insurance, Diagnosis, Psychiatry, Incidence, Prudential Financial, Mortality, Multiple sclerosis, Mutual, Corebridge Financial, Comorbidity, John Hancock Financial, Pharmaceutical industry

Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.

Key Points: 
  • Michelle Zieba, Vice President of Sales, described the life insurance application process, "After receiving initial quotes, our MS customers will then be advised by our life insurance experts as to which plan is best.
  • A small number of people with Multiple Sclerosis experience very mild symptoms and little to no disability.
  • Zieba offered this advice to those with MS who are shopping for life insurance, "MS patients can do a lot to prepare to buy life insurance.
  • Instant life insurance quotes for those with Multiple Sclerosis of all severities are available at www.lifequotes.com .

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
Tuesday, March 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
Tuesday, March 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Retrieve Medical Holdings, Inc. Forges Partnership with Louisiana Health System Hospitals

Retrieved on: 
Monday, February 26, 2024
Hospital, Roger Hawkins (drummer), Comorbidity, Bed, OTC Markets Group, CMI, Documentation, Emergency department, American College, Emergency, Patient, Retrieval, Partnership, Nursing

The company's wholly owned subsidiary, Retrieve Medical, Inc. ("Retrieve"), has signed a pivotal contract to deploy its cutting-edge software at a prominent Louisiana hospital.

Key Points: 
  • The company's wholly owned subsidiary, Retrieve Medical, Inc. ("Retrieve"), has signed a pivotal contract to deploy its cutting-edge software at a prominent Louisiana hospital.
  • The agreement marks Retrieve's continued expansion into the healthcare landscape, bolstering its portfolio with another esteemed community health system.
  • "We are pleased to broaden our reach into yet another community health system," commented Dr. Mark Rosenberg, Chairman of Retrieve and Past President of the American College of Emergency Physicians.
  • "This partnership underscores our position as the premier provider of physician documentation software for hospitals and medical systems throughout the United States.

2023 in Review: Healthcare Triumphs and the Top Five Trends Shaping Healthcare in 2024

Retrieved on: 
Wednesday, January 31, 2024
Practice Management, Technology, Managed Care, Health, General Health, Mental Health, Health Technology, Software, Artificial Intelligence, Hospitals, Telemedicine, Virtual Medicine, Shift, Comorbidity, Patient satisfaction, University of Connecticut, Social, Intuition, Telehealth, Social determinants of health, Machine learning, Patient, Medicaid, Physical, SDOH, Artificial intelligence, Pharmacy, Community, Organization, Hospital

Bamboo Health , the leader in Real-Time Care Intelligence™, today announced the release of the company’s 2023 Annual Impact Report, outlining the transformative achievements of top healthcare organizations and introducing five key healthcare trends expected in 2024.

Key Points: 
  • Bamboo Health , the leader in Real-Time Care Intelligence™, today announced the release of the company’s 2023 Annual Impact Report, outlining the transformative achievements of top healthcare organizations and introducing five key healthcare trends expected in 2024.
  • In 2023, Bamboo Health impacted 1 billion patient encounters, involving 2,500 hospitals, 8,000 post-acute facilities, 25,000 pharmacies, 32 health plans, 50 state governments and 1 million providers.
  • Jeff Smith, Bamboo Health’s CEO, credited the company's success to its focus on integrating the entire spectrum of patient health needs.
  • To learn more about Bamboo Health’s 2023 successes and the anticipated trends for 2024, view the Annual Impact Report .

Airfinity launches world’s first obesity data and analytics platform

Retrieved on: 
Wednesday, January 24, 2024
Obesity, Benchmarking, Eli Lilly, Comorbidity, Novo Nordisk, Gold, Weight loss, Pharmaceutical industry

London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market.

Key Points: 
  • London, England, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Today, Airfinity is launching the world’s first data and analytics platform dedicated to the breakthrough obesity treatments market.
  • Our models estimate the obesity drug market will generate sales of $80bn in the US alone by the end of the decade.
  • Airfinity’s data solution and expert analysts will help clients navigate the evolving market through data simulations and predictive modelling.
  • Airfinity Chief Medical Officer, Dr Henrik Sillesen, says, “Obesity drugs are a modern day gold rush for drugmakers.

VIVUS Provides Update on Pipeline and Program Milestones

Retrieved on: 
Monday, January 8, 2024
Patient, Quality of life, HIV/AIDS, Bloating, Diarrhea, Inflammatory bowel disease, ABPM, Chronic pain, Enzyme replacement therapy, Cystic fibrosis, Heart, Degenerative disease, Exocrine pancreatic insufficiency, Comorbidity, Steatorrhea, Obesity, HIV, Amylase, Orthostatic hypertension, Phentermine, Heart failure, Exercise, Pharmaceutical industry

CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.

Key Points: 
  • CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, today announced pipeline updates and program milestones.
  • “VIVUS has been continuously dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases, including exocrine pancreatic insufficiency, obesity and pulmonary arterial hypertension,” said John Amos, Chief Executive Officer at VIVUS LLC.
  • QSYMIA® is now the number one branded oral product in the US for obesity treatment.
  • Moreover, VIVUS is actively developing pipeline products focusing on bone marrow transplant preparation (VI-0609) and diabetes treatments (VI-0809 and VI-0810).”

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Retrieved on: 
Monday, January 8, 2024
Blood pressure, Bradycardia, Risk, Orchestra, Collection, Consultant, Hypertension, Mortality, Disease, HOPE, Stroke, Comorbidity, Patient, Safety, Heart failure, Beat (music), BioMed Central, OSBP, Pharmaceutical industry

AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.

Key Points: 
  • AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure.
  • Orchestra BioMed and Medtronic, Inc. (NYSE: MDT) (“Medtronic”) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022.
  • Orchestra BioMed is actively screening patients for enrollment in the BACKBEAT pivotal study.
  • The study will randomize approximately 500 patients 1:1 to AVIM therapy combined with continued medical therapy (treatment) or continued medical therapy and standard pacing alone (control).